BLRX

BioLineRx Ltd

BLRX.US biolinerx.com
2.57
+0.02 (+0.76%)
USD · NASDAQ
52-week range
2.15
4.56
Trading at 17% of the 52-week range
Market Cap
12.36M
P/E Ratio
0.00
Forward P/E
93.46
Book Value
3.00
Div. Yield
N/A
% Institutions
1.37%
% Insiders
3.52%

1 Year

-39.4%

3 Year

-96.8%

10 Year

-99.5%
Description

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Company Information

Company Name
BioLineRx Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09071M3043
CIK: 0001498403
CUSIP: 09071M205
Currency: USD
Full Time Employees: 20
Phone: 972 8 642 9100
Fiscal Year End: December
IPO Date: Jul 25, 2011
Description:

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Address:

Modi?in Technology Park, Hevel Modi'in, Israel, 7177871

People

Directors & Officers

Name Title Year Born
Mr. Philip A. Serlin CPA, M.B.A. Chief Executive Officer 1960
Ms. Mali Zeevi CPA Chief Financial Officer 1976
Dr. Ella Sorani Ph.D. Chief Development Officer 1968
Mr. John Lacey Head of Corporate Communications & Investor Relations NA
Mr. Raziel Fried Treasurer & Budgetary Control Director NA

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
XTX Topco Ltd 10.94K Mar 31, 2026 0.25% $0.00 0.00%
Rhumbline Advisers 2.35K Mar 31, 2026 0.05% $0.00 -29.82%
BNP Paribas Arbitrage, SA 1.80K Mar 31, 2026 0.04% $0.00 20.00%
Wells Fargo & Co 1.75K Mar 31, 2026 0.04% $0.00 0.00%
Citigroup Inc 1.73K Mar 31, 2026 0.04% $0.00 -15.21%
UBS Group AG 529.00 Mar 31, 2026 0.01% $0.00 -72.89%
Goss Wealth Management LLC 107.00 Mar 31, 2026 0.00% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 100.00 Mar 31, 2026 0.00% $0.00 0.00%
Advisor Group Holdings, Inc. 26.00 Mar 31, 2026 0.00% $0.00 0.00%
Rockefeller Capital Management L.P. 12.00 Mar 31, 2026 0.00% $0.00 0.00%
Danske Bank A/S. 2.00 Jun 30, 2026 0.00% $0.00 0.00%
Citadel Advisors Llc 0.00 Mar 31, 2026 0.00% $0.00 -100.00%
Bank of America Corp 0.00 Mar 31, 2026 0.00% $0.00 -100.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Nasdaq Composite Index 999.00 0.04% ▲ 0.00% Mar 31, 2025

Financial Highlights

Market Cap: $12.36M
EBITDA: $-12.12M
P/E Ratio: $0.00
PEG Ratio: $0.20
Book Value: $3.00
Earnings/Share: $0.00
Profit Margin: 0.00%
Operating Margin: -1,215.31%
ROA (TTM): -19.82%
ROE (TTM): -55.27%
Revenue (TTM): $1.39M
Revenue/Share (TTM): $0.60
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -3.30%

Valuation Metrics

Enterprise Value: $7.41M
Trailing P/E: 0.00
Forward P/E: 93.46

Shares Statistics

Shares Outstanding: 4.85M
Shares Float: 4.11M
% Insiders: 3.52%
% Institutions: 1.37%
Short % Float: 3.09%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$1.19M
Cost of Goods Sold
adjust
$-758.97K
Gross Profit
subtotal
$430.39K
SG&A
adjust
$-3.92M
R&D
adjust
$-7.66M
Operating Income
subtotal
$-10.37M
Other / Non-Operating Items
adjust
$9.18M
Net Income
subtotal
$-1.18M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BLRX.US!